Tympanostomy tube evaluation — also referred to as ear tube candidacy assessment, ventilation tube referral, or surgical escalation for otitis media with effusion — is a clinical decision point, not an automatic next step after a set number of weeks. The decision is shaped by the duration and laterality of effusion, documented hearing impact, developmental risk, and whether the burden of disease justifies procedural intervention.

Tympanostomy tube insertion is the most commonly performed ambulatory surgery in children in the United States, with approximately 667,000 procedures annually. Despite its prevalence, the decision to refer for tubes requires careful consideration of whether the clinical picture has crossed the threshold where observation and non-surgical management are no longer sufficient. This article addresses when that threshold is reached, what clinicians and families should discuss before proceeding, and where non-surgical options remain relevant in the management pathway.

When should OME move from observation to tympanostomy tube evaluation?

OME should be evaluated for tympanostomy tube placement when bilateral chronic OME — effusion present for three months or more — is accompanied by documented hearing loss, or when OME of any duration is present in a child at increased developmental risk. Recurrent acute otitis media with middle ear effusion present at the time of assessment is also a recognized indication.

The AAO-HNSF 2022 tympanostomy tube guideline identifies the following clinical indications for which tube insertion should be offered:

  • Bilateral chronic OME for three months or more with documented hearing loss — this is the primary indication for otherwise healthy children. Duration alone is insufficient; audiometric confirmation of hearing loss is required.
  • Bilateral or unilateral chronic OME for three months or more with symptoms attributable to OME — including balance problems, poor school performance, behavioural changes, ear discomfort, or reduced quality of life, even in the absence of formally documented hearing loss.
  • Recurrent acute otitis media with effusion present at assessment — defined as three or more well-documented AOM episodes within six months, or four or more within twelve months with at least one in the preceding six months, and middle ear effusion confirmed at the time of tube candidacy evaluation.
  • At-risk children with unilateral or bilateral OME — including those with permanent hearing loss independent of OME, Down syndrome, cleft palate, autism spectrum disorder, developmental delay, learning disorder, ADHD, blindness or uncorrectable visual impairment, or other craniofacial syndromes. For at-risk children, a flat (Type B) tympanogram or documented effusion of three months or more is sufficient — audiometric hearing loss need not be confirmed separately.

 

A critical point for primary care clinicians: the guideline specifies that tubes should be offered, not automatically performed. The decision is a shared one, informed by the clinical picture and family preferences. Referral to ENT is the appropriate next step when these thresholds are reached — the ENT surgeon then confirms candidacy and discusses the procedure.

For adults, there are no equivalent consensus guidelines. Tympanostomy tube evaluation in adults is appropriate when chronic Eustachian tube dysfunction leads to persistent OME, middle ear atelectasis, or a retracted and flaccid eardrum unresponsive to three to twelve months of maximal medical management.

What should clinicians discuss before tympanostomy tube placement?

Before tympanostomy tube placement, clinicians should ensure families understand the procedure’s purpose, expected duration, follow-up requirements, common complications — particularly otorrhea — and the realistic scope of what tubes do and do not accomplish.

Procedure and anaesthesia: Tympanostomy tube insertion involves a small incision in the eardrum (myringotomy), aspiration of any middle ear effusion, and placement of a small plastic or metal ventilation tube through the incision. In children, the procedure is performed under general anaesthesia and typically takes a few minutes. Older adolescents and adults may tolerate the procedure under local anaesthesia in an office setting.

Tube duration: Short-term tubes remain in place for approximately six to fifteen months before extruding spontaneously as the eardrum heals. Long-term tubes are designed to remain for longer and may require surgical removal. Approximately 14% of children require a second set of tubes within five years.

Otorrhea: The most common complication, occurring in 16% of children within four weeks of insertion and in up to 26% over the tube’s lifespan. It is typically managed with topical antibiotic ear drops. Post-insertion drops are often given prophylactically.

Water precautions: Evidence on the necessity of water precautions is mixed. Most surgeons recommend avoiding submersion initially, but surface water exposure during bathing is not consistently associated with increased otorrhea rates.

What tubes do — and do not — accomplish: Tubes restore middle ear ventilation and improve hearing in the short term. However, a landmark randomised controlled trial (Hoberman et al., NEJM 2021) found that tube placement did not significantly reduce AOM recurrence rates compared to medical management — the primary benefit is enabling topical antibiotic treatment of future infections rather than preventing them. Families should understand this before proceeding.

Persistent perforation occurs in 1% to 6% of cases following tube extrusion and may require myringoplasty. Tympanosclerosis is common but rarely clinically significant.

How can non-surgical options fit before or alongside escalation?

Non-surgical options — principally autoinflation of the Eustachian tube — remain relevant throughout the OME management pathway, including in the period before the surgical threshold is reached and alongside monitoring when families are weighing options or when the clinical indication for tubes is borderline.

The AAO-HNSF 2016 OME guideline specifically endorses autoinflation as a non-surgical intervention during the surveillance period. This is not a vague recommendation — it is the only home-based intervention the guideline names and endorses. Clinicians can recommend it at any point in the monitoring period, not only after three months have elapsed.

The practical value of autoinflation in the escalation conversation is twofold:

First, it gives families an active, evidence-based option during the period when observation alone feels insufficient. Parents frequently present asking for antibiotics or accelerated surgical referral before the formal threshold has been reached. Antibiotics are not indicated for OME without active infection. Autoinflation is a substantive clinical response to that pressure — it addresses the negative middle ear pressure directly and is supported by published clinical evidence.

Second, for children with borderline findings — effusion present but hearing loss mild, or duration approaching but not yet at three months — autoinflation can be offered as an active monitoring strategy that may reduce the probability of reaching the surgical threshold.

For a detailed review of autoinflation evidence, device considerations, and patient selection, see [Autoinflation as a Non-Surgical Option in Pediatric OME Management].

How Earflo supports clinician-led OME management

When OME monitoring findings approach or reach the threshold for tympanostomy tube evaluation, Earflo provides a clinically meaningful option for families who want to act before surgery is confirmed, or for whom the surgical indication is present but the family prefers a non-surgical approach first.

Earflo is FDA-cleared for the management of negative middle ear pressure and OME in patients from age two, and is equally applicable in adults with Eustachian tube dysfunction and chronic OME where the surgical threshold discussion differs from paediatric practice.

The mechanism: Earflo uses swallow-coordinated autoinflation — delivering a precisely timed puff of air during the natural opening of the Eustachian tube that occurs with every swallow. Unlike conventional autoinflation devices that require forceful blowing against a closed tube, Earflo works at significantly lower pressure, eliminates aspiration risk, and causes no discomfort. There is no technique to learn and no risk of overpressurization.

Training and compliance tools: A built-in light indicator provides real-time feedback on correct technique and successful swallow detection. A companion app tracks compliance over time — contributing to the 99% objective compliance rate across both published clinical studies, substantially higher than conventional nasal balloon autoinflation compliance rates (Webster et al., Cochrane 2023).

The evidence: Two published clinical studies (Soto et al., OTO Open 2025; Hura et al., American Journal of Otolaryngology 2026) confirmed 99% compliance, an average 12.9–14.2 dB hearing improvement at two weeks, 91% tympanometric improvement during active use, and 89% of children avoiding tympanostomy tube surgery — including children who had already met the criteria for tube placement. No adverse events were reported.

For a structured overview of the full OME management pathway, see [Pediatric OME Clinical Management: Monitoring, Treatment Pathways, and Escalation].

Key takeaways

  • Tympanostomy tube evaluation is indicated for bilateral chronic OME with documented hearing loss, OME with quality-of-life impact, recurrent AOM with effusion at assessment, and OME of any duration in at-risk children
  • The primary benefit of tubes is enabling topical antibiotic treatment of future infections and restoring short-term hearing — not preventing AOM recurrence, as confirmed by a landmark NEJM RCT
  • Otorrhea is the most common complication, occurring in up to 26% of children over the tube’s lifespan; persistent perforation occurs in 1–6% after extrusion
  • Non-surgical autoinflation can be recommended at any point in the monitoring period — not only after three months — and is the only home-based intervention specifically endorsed by the AAO-HNSF OME guideline
  • Earflo’s swallow-coordinated mechanism eliminates aspiration risk, works at lower pressure, causes no discomfort, and provides light and app-based feedback; two published studies confirm 99% compliance and 89% surgery avoidance

    Learn more about Earflo for clinicians →

Contact us to discuss clinical integration →

About the Author

Dr. Peter Santa Maria, MD, PhD Professor & Division Chief of Otology and Neurotology Vice Chair of Translational and Clinical Research, University of Pittsburgh

Dr. Santa Maria is an ear surgeon-scientist specializing in advanced ear disease, hearing loss, and Eustachian tube disorders. He is the principal investigator of the two published clinical studies on swallow-coordinated autoinflation cited in this article, and co-founder and Chief Medical Officer of Earflo, Inc.

Disclosure: Dr. Santa Maria is a co-inventor of Earflo and holds equity in the company.

References

  • Rosenfeld RM, Tunkel DE, Schwartz SR, et al. Clinical Practice Guideline: Tympanostomy Tubes in Children (Update). Otolaryngology–Head and Neck Surgery. 2022;166(1_suppl):S1–S55. doi:10.1177/01945998211065662. PMID: 35138954.
  • Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). Otolaryngology–Head and Neck Surgery. 2016;154(1 Suppl):S1–S41. PMID: 26832942.
  • Hoberman A, Preciado D, Paradise JL, et al. Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media. New England Journal of Medicine. 2021;384(18):1739–1750. doi:10.1056/NEJMoa2027278. PMID: 33951359.
  • Spaw M, Agarwal N, Camacho M. Tympanostomy Tube Insertion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan. Updated 2024 Mar 5. PMID: 33351417.
  • Kay DJ, Nelson M, Rosenfeld RM. Meta-analysis of tympanostomy tube sequelae. Otolaryngology–Head and Neck Surgery. 2001;124(4):374–380. doi:10.1067/mhn.2001.114906. PMID: 11283489.
  • Soto MJ, Hura N, Oldakowska I, Oldakowski M, Bumbak P, Santa Maria PL. Feasibility of a Novel Autoinflation Device to Treat Pediatric Otitis Media With Effusion At-Home. OTO Open. 2025;9(2):e70128. doi:10.1002/oto2.70128. PMID: 40370996.
  • Hura N, Soto MJ, Lalwani Z, Oldakowska I, Oldakowski M, Bumbak P, Santa Maria PL. A novel autoinflation device for persistent pediatric otitis media with effusion: A prospective single-arm cohort study. American Journal of Otolaryngology. 2026;47(4):104862. doi:10.1016/j.amjoto.2026.104862. PMID: 42296786.
  • Webster KE, Mulvaney CA, Galbraith K, Rana M, Marom T, Daniel M, Venekamp RP, Schilder AGM, MacKeith S. Autoinflation for otitis media with effusion (OME) in children. Cochrane Database of Systematic Reviews. 2023;(9):CD015253. doi:10.1002/14651858.CD015253.pub2. PMID: 37750500.